Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Target Price at $18.00

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

EPRX has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Stifel Nicolaus assumed coverage on Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a “buy” rating and a $25.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday. Finally, Wall Street Zen downgraded Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Affinity Asset Advisors LLC boosted its stake in shares of Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after buying an additional 1,289,005 shares during the period. Vivo Capital LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth $7,965,000. Ally Bridge Group NY LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the third quarter worth $5,398,000. Seven Fleet Capital Management LP purchased a new stake in shares of Eupraxia Pharmaceuticals during the first quarter worth $5,137,000. Finally, Redmile Group LLC acquired a new stake in Eupraxia Pharmaceuticals during the first quarter valued at $5,068,000.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $6.52 on Thursday. The company has a 50-day moving average of $6.67 and a two-hundred day moving average of $7.41. The stock has a market cap of $423.92 million, a price-to-earnings ratio of -6.21 and a beta of 1.05. The company has a debt-to-equity ratio of 0.02, a current ratio of 19.31 and a quick ratio of 19.31. Eupraxia Pharmaceuticals has a one year low of $4.88 and a one year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, equities research analysts expect that Eupraxia Pharmaceuticals will post -0.88 earnings per share for the current year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.